InvestSMART

Imricor Medical Systems Inc (ASX: IMR) - Announcements

- Current share price for IMR : $1.585

ASX company news and announcements for Imricor Medical Systems Inc (IMR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imricor Medical Systems Inc (IMR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imricor Medical Systems Inc (IMR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imricor Medical Systems Inc (IMR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$568 Application for quotation of securities - IMR 24 Feb 2022 5:13PM $0.755 $1.585 risen by 109.93%
$568 FY21 Results Investor Presentation 24 Feb 2022 8:40AM $0.800 $1.585 risen by 98.13%
$568 Imricor Releases FY21 Results 24 Feb 2022 8:38AM $0.800 $1.585 risen by 98.13%
$568 Appendix 4E and FY21 Financial Accounts 24 Feb 2022 8:36AM $0.800 $1.585 risen by 98.13%
$568 Munster University Hospital Performs First iCMR Procesure 21 Feb 2022 10:01AM $0.820 $1.585 risen by 93.29%
$568 Leadership Team Update 11 Feb 2022 3:44PM $0.900 $1.585 risen by 76.11%
$568 Details of FY21 Results Investor Briefing 28 Jan 2022 9:06AM $0.990 $1.585 risen by 60.10%
$568 Appendix 4C - Quarterly Report and Business Update 27 Jan 2022 8:16AM $1.000 $1.585 risen by 58.50%
$568 Upcoming Investor Conference Call for Dec Quarterly Report 21 Jan 2022 10:46AM $1.120 $1.585 risen by 41.52%
$568 Change in substantial holding 11 Jan 2022 9:49AM $1.085 $1.585 risen by 46.08%
$568 Imricor Adds Fourteenth Site and First in Greece 4 Jan 2022 8:28AM $1.005 $1.585 risen by 57.71%
$568 Imricor Enrolls Two More Sites in Berlin 24 Dec 2021 9:16AM $0.990 $1.585 risen by 60.10%
$568 Strategic Investment in MiRTLE Medical 29 Nov 2021 9:12AM $1.220 $1.585 risen by 29.92%
$568 Application for FDA Investigational Device Exemption 24 Nov 2021 10:51AM $1.315 $1.585 risen by 20.53%
$568 Appendix 4C - Quarterly Report and Business Update 28 Oct 2021 8:57AM $1.430 $1.585 risen by 10.84%
$568 Becoming a substantial holder 27 Oct 2021 8:24AM $1.440 $1.585 risen by 10.07%
$568 Supplementary Disclosure on Semmelweis Purchase Agreement 20 Oct 2021 8:47AM $1.220 $1.585 risen by 29.92%
$568 Application for quotation of securities - IMR 14 Oct 2021 10:11AM $1.205 $1.585 risen by 31.54%
$568 New Lab Adoption at Semmelweis University in Hungary 12 Oct 2021 9:43AM $1.135 $1.585 risen by 39.65%
$568 Imricor Completes SPP 12 Oct 2021 9:35AM $1.135 $1.585 risen by 39.65%
$568 MiRTLE Sales Agreement Clarification and Business Update 30 Sep 2021 1:35PM $1.170 $1.585 risen by 35.47%
$568 Imricor Signs Sales Agreement with MiRTLE Medical 28 Sep 2021 9:43AM $1.225 $1.585 risen by 29.39%
$568 Change in Substantial Holding 21 Sep 2021 8:53AM $1.200 $1.585 risen by 32.08%
$568 Becoming a substantial holder 16 Sep 2021 4:50PM $1.140 $1.585 risen by 39.04%
$568 Security Purchase Plan Booklet Sent to Eligible Holders 15 Sep 2021 3:12PM $1.110 $1.585 risen by 42.79%

401 - 425 of 602 results

Page 17 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.